Moolec Science (MLECW) Debt Ratio (2022 - 2025)

Moolec Science (MLECW) posted Debt Ratio of 1.12 for Q2 2025, down 9.52% sequentially from 1.23 in Q4 2024, and up 193.3% YoY from 0.38 in Q2 2024.

Moolec Science (MLECW) Debt Ratio (2022 - 2025) Analysis & Trends

Moolec Science has reported Debt Ratio for 4 years, with the latest figure at 1.12 in Q2 2025.

Quarterly Debt Ratio rose 193.3% year-over-year to 1.12 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 1.12 (up 193.3% YoY) and the FY2025 annual result came in at 1.12, up 193.3% from the prior year.
Debt Ratio slipped to 1.12 in Q2 2025 per MLECW's latest filing, from 1.23 in the prior quarter.
Over five years, Debt Ratio peaked at 1.23 in Q4 2024 and troughed at 0.0 in Q2 2022.
A 4-year average of 0.49 and a median of 0.41 in 2024 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2023 and 2024: Debt Ratio jumped 293581.45% in 2023, then sank 36.97% in 2024.
Over 4 years, Debt Ratio stood at 0.04 in 2022, then jumped by 1646.23% to 0.63 in 2023, then soared by 95.51% to 1.23 in 2024, then declined by 9.52% to 1.12 in 2025.
According to Business Quant data, Debt Ratio over the past three periods registered 1.12, 1.23, and 0.56 for Q2 2025, Q4 2024, and Q3 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Moolec Science	8,617.72	-1.19 Mn	-	-

Download Data